ASeq Newsletter

ASeq Newsletter

Share this post

ASeq Newsletter
ASeq Newsletter
Mission Biosciences

Mission Biosciences

Jul 18, 2024
∙ Paid
2

Share this post

ASeq Newsletter
ASeq Newsletter
Mission Biosciences
Share

Someone asked about Mission Bio on my Fluent post. Specifically, if 10X have IP covering droplet based encapsulation, why haven’t they sued Mission?

This is a good question. I don’t see any public information on licensing agreements, but it’s possible they exist. They might also need BioRad’s IP (currently cross-licensed to 10X).

However I suspect it may come down to details of the fluidic implementation in Mission Bio’s products.

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Nava Whiteford
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share